Home ETF List About

Portfolio Holdings Detail for ISIN IE0003WV2ME7
Stock Name / FundiShares S&P 500 Equal Weight UCITS ETF GBP Hedged (Acc)
IssuerBlackrock
Entity holding fund iShares III Public Limited Company
Entity Type
Entity LEI 549300PZLRJB7M8H1057
ETF TickerISPE(GBP) LSE
ETF TickerISPE.L(GBP) LSE

Holdings detail for INCY

Stock NameIncyte Corporation
TickerINCY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45337C1027
LEI549300Z4WN6JVZ3T4680

Show aggregate INCY holdings

News associated with INCY

Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib
(RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY)
Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00
Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY)
Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC
Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY)
Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC
Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)
Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY)
State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY)
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY)
Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY)
Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus
Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures (ESM25 ) are up +1.00%, and June E-mini Nasdaq futures... - 2025-06-17 13:23:43

iShares S&P 500 Equal Weight UCITS ETF GBP Hedged (Acc) INCY holdings

DateNumber of INCY Shares HeldBase Market Value of INCY SharesLocal Market Value of INCY SharesChange in INCY Shares HeldChange in INCY Base ValueCurrent Price per INCY Share HeldPrevious Price per INCY Share Held
2025-09-18 (Thursday)127,542INCY holding increased by 150USD 10,968,612INCY holding increased by 165770USD 10,968,612150USD 165,770 USD 86 USD 84.8
2025-09-17 (Wednesday)127,392USD 10,802,842INCY holding increased by 114653USD 10,802,8420USD 114,653 USD 84.8 USD 83.9
2025-09-16 (Tuesday)127,392USD 10,688,189INCY holding increased by 96818USD 10,688,1890USD 96,818 USD 83.9 USD 83.14
2025-09-15 (Monday)127,392USD 10,591,371INCY holding increased by 5096USD 10,591,3710USD 5,096 USD 83.14 USD 83.1
2025-09-12 (Friday)127,392USD 10,586,275USD 10,586,275
2025-09-10 (Wednesday)127,392USD 10,987,560USD 10,987,560
2025-09-09 (Tuesday)127,467USD 10,911,175USD 10,911,175
2025-09-08 (Monday)127,467USD 11,033,544USD 11,033,544
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INCY by Blackrock for IE0003WV2ME7

Show aggregate share trades of INCY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-18BUY150 86.000* 68.94
2025-08-18BUY138 84.920* 68.62
2025-08-12SELL-75 81.610* 68.28 Profit of 5,121 on sale
2025-07-29BUY80 77.375* 68.14
2025-07-23SELL-225 70.690* 68.11 Profit of 15,324 on sale
2025-07-22SELL-456 68.900* 68.10 Profit of 31,054 on sale
2025-07-21SELL-152 67.380* 68.11 Profit of 10,352 on sale
2025-07-18SELL-380 67.860* 68.11 Profit of 25,880 on sale
2025-07-15SELL-152 68.250* 68.09 Profit of 10,350 on sale
2025-07-14SELL-375 69.980* 68.08 Profit of 25,532 on sale
2025-07-11SELL-225 68.590* 68.08 Profit of 15,318 on sale
2025-07-10SELL-900 70.340* 68.07 Profit of 61,261 on sale
2025-07-09SELL-300 68.720* 68.06 Profit of 20,419 on sale
2025-07-08SELL-975 67.670* 68.07 Profit of 66,365 on sale
2025-07-03SELL-1,292 68.450* 68.07 Profit of 87,942 on sale
2025-07-02SELL-231 68.170* 68.07 Profit of 15,723 on sale
2025-06-30BUY3,277 68.100* 68.07
2025-06-27SELL-3,626 68.370* 68.06 Profit of 246,801 on sale
2025-06-25BUY74 67.550* 68.05
2025-06-24SELL-2,738 69.010* 68.04 Profit of 186,307 on sale
2025-06-23SELL-74 67.260* 68.05 Profit of 5,036 on sale
2025-06-20BUY148 68.460* 68.05
2025-06-18SELL-444 68.270* 68.04 Profit of 30,212 on sale
2025-06-17BUY3,271 68.810* 68.04
2025-06-11SELL-216 68.850* 68.03 Profit of 14,694 on sale
2025-06-10SELL-504 70.070* 68.01 Profit of 34,279 on sale
2025-06-06SELL-144 68.770* 68.00 Profit of 9,792 on sale
2025-06-05SELL-1,224 67.240* 68.00 Profit of 83,234 on sale
2025-06-02SELL-5,832 65.310* 68.03 Profit of 396,748 on sale
2025-05-30SELL-1,296 65.060* 68.05 Profit of 88,192 on sale
2025-05-29SELL-144 66.040* 68.06 Profit of 9,801 on sale
2025-05-27SELL-144 65.350* 68.10 Profit of 9,807 on sale
2025-05-23SELL-216 64.245* 68.16 Profit of 14,722 on sale
2025-05-16SELL-1,080 63.310* 68.29 Profit of 73,757 on sale
2025-05-15SELL-216 62.760* 68.33 Profit of 14,760 on sale
2025-05-13SELL-72 60.810* 68.44 Profit of 4,928 on sale
2025-05-12SELL-504 60.850* 68.50 Profit of 34,523 on sale
2025-05-09SELL-432 58.980* 68.57 Profit of 29,622 on sale
2025-05-08SELL-2,088 59.730* 68.64 Profit of 143,311 on sale
2025-05-07SELL-144 59.550* 68.70 Profit of 9,893 on sale
2025-05-06BUY48 59.610* 68.77
2025-05-01BUY2,736 62.030* 68.93
2025-04-30BUY1,512 62.660* 68.98
2025-04-29SELL-288 60.430* 69.04 Profit of 19,885 on sale
2025-04-28SELL-350 59.520* 69.12 Profit of 24,192 on sale
2025-04-25BUY144 59.160* 69.20
2025-04-24SELL-72 58.970* 69.28 Profit of 4,988 on sale
2025-04-22SELL-9,648 57.380* 69.48 Profit of 670,305 on sale
2025-04-17SELL-4,392 58.210* 69.77 Profit of 306,449 on sale
2025-04-16BUY144 57.730* 69.88
2025-04-15BUY144 58.460* 69.98
2025-04-10SELL-4,536 55.170* 70.32 Profit of 318,962 on sale
2025-04-09BUY360 58.860* 70.42
2025-04-08BUY72 56.970* 70.54
2025-04-07BUY1,278 60.290* 70.63
2025-04-04BUY781 60.580* 70.73
2025-04-02BUY497 62.330* 70.80
2025-04-01BUY5,687 60.910* 70.90
2025-03-31BUY216 60.550* 70.99
2025-03-25BUY72 62.080* 71.38
2025-03-20BUY144 60.580* 71.67
2025-03-18BUY360 60.000* 71.91
2025-03-17BUY47 62.010* 72.01
2025-03-14SELL-25 67.860* 72.06 Profit of 1,801 on sale
2025-03-13SELL-4,645 67.710* 72.10 Profit of 334,915 on sale
2025-03-12BUY864 67.730* 72.15
2025-03-11BUY864 68.070* 72.19
2025-03-07BUY288 70.790* 72.22
2025-03-06BUY1,008 70.090* 72.25
2025-03-05BUY5,472 69.810* 72.27
2025-03-04BUY288 69.680* 72.30
2025-03-03BUY360 70.260* 72.33
2025-02-28BUY720 73.500* 72.31
2025-02-27BUY648 73.180* 72.30
2025-02-26SELL-375 74.300* 72.28 Profit of 27,104 on sale
2025-02-25SELL-72 74.400* 72.25 Profit of 5,202 on sale
2025-02-24BUY72 74.010* 72.23
2025-02-20SELL-936 71.380* 72.24 Profit of 67,619 on sale
2025-02-19BUY288 70.160* 72.27
2025-02-18BUY294 71.270* 72.28
2025-02-13BUY8,208 70.010* 72.36
2025-02-12BUY2,448 69.050* 72.41
2025-02-11BUY2,021 66.330* 72.49
2025-02-07BUY216 74.130* 72.53
2025-02-06BUY2,880 74.950* 72.49
2025-02-05BUY1,440 75.260* 72.45
2025-02-04BUY1,080 74.120* 72.43
2025-02-03SELL-6,264 73.740* 72.41 Profit of 453,572 on sale
2025-01-31BUY576 74.160* 72.38
2025-01-30BUY72 73.770* 72.36
2025-01-29BUY1,224 73.720* 72.34
2025-01-28BUY432 73.150* 72.33
2025-01-27BUY432 72.640* 72.32
2025-01-24BUY432 72.590* 72.32
2025-01-23BUY1,224 72.530* 72.31
2025-01-22BUY720 72.410* 72.31
2025-01-21BUY4,248 73.470* 72.29
2025-01-17BUY864 71.930* 72.30
2025-01-15BUY432 72.460* 72.30
2025-01-13BUY1,224 72.370* 72.30
2025-01-10BUY937 70.540* 72.34
2024-12-31BUY216 69.070* 72.44
2024-12-30SELL-5,267 68.420* 72.53 Profit of 381,994 on sale
2024-12-27BUY1,396 69.230* 72.60
2024-12-23BUY432 69.840* 72.81
2024-12-20SELL-9,915 68.840* 72.91 Profit of 722,875 on sale
2024-12-19BUY948 67.060* 73.06
2024-12-17BUY715 69.400* 73.30
2024-12-16BUY237 69.800* 73.40
2024-12-13BUY395 68.550* 73.54
2024-12-11BUY237 72.490* 73.57
2024-12-10BUY158 72.480* 73.60
2024-12-09BUY158 72.110* 73.65
2024-12-05SELL-474 74.920* 73.53 Profit of 34,855 on sale
2024-12-04BUY80 74.620* 73.50
2024-12-02BUY316 73.240* 73.56
2024-11-29BUY1,404 74.590* 73.52
2024-11-27BUY312 75.450* 73.36
2024-11-26BUY780 74.800* 73.30
2024-11-25BUY9,672 73.520* 73.29
2024-11-22BUY234 71.720* 73.36
2024-11-21BUY234 70.390* 73.51
2024-11-20BUY1,014 71.050* 73.64
2024-11-19SELL-1,014 70.560* 73.81 Profit of 74,844 on sale
2024-11-18BUY4,680 76.970* 73.62
2024-11-12BUY936 80.580* 73.19
2024-11-11BUY234 81.530* 72.63
2024-11-08BUY940 83.380* 71.87
2024-11-07BUY1,584 82.340* 71.06
2024-11-06BUY702 80.950* 70.24
2024-11-05BUY156 77.280* 69.60
2024-11-04BUY805 75.750* 68.98
2024-11-01BUY390 76.130* 68.19
2024-10-30BUY231 73.930* 66.52
2024-10-29BUY1,463 73.600* 65.34
2024-10-25BUY308 65.070* 65.32
2024-10-24BUY231 65.240* 65.34
2024-10-22BUY462 65.590* 65.27
2024-10-21BUY385 65.270* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INCY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19321,923395451,11071.4%
2025-09-18244,9471,423469,74752.1%
2025-09-17277,858779546,95350.8%
2025-09-16359,781946576,37962.4%
2025-09-15347,4534582,22859.7%
2025-09-12353,0400631,53455.9%
2025-09-11448,7333,894739,70160.7%
2025-09-10490,727248671,93273.0%
2025-09-09515,3951,822682,79175.5%
2025-09-08308,184119479,82864.2%
2025-09-05256,7192,505512,04950.1%
2025-09-04422,6241,507834,71750.6%
2025-09-03381,6797,777624,92261.1%
2025-09-02547,12015,396816,26767.0%
2025-08-29148,294262304,42748.7%
2025-08-28164,0080347,48047.2%
2025-08-27248,926453513,40148.5%
2025-08-26365,1306709,32051.5%
2025-08-25478,1301,306642,31974.4%
2025-08-22344,3522,023596,30157.7%
2025-08-21198,7294,881335,30159.3%
2025-08-20351,6993,977555,34563.3%
2025-08-19343,1103,146574,32859.7%
2025-08-18366,1244,996653,10356.1%
2025-08-15480,8858,035625,79776.8%
2025-08-14593,55436,654806,06873.6%
2025-08-13845,18198,1601,257,50367.2%
2025-08-12462,89642,208678,68968.2%
2025-08-11385,211696595,89264.6%
2025-08-08248,925738426,18758.4%
2025-08-07268,864929420,48663.9%
2025-08-06554,642891731,48475.8%
2025-08-05361,6872,092623,87958.0%
2025-08-04338,0051,464519,15065.1%
2025-08-01414,814828572,87972.4%
2025-07-31570,8456,148777,41773.4%
2025-07-30471,30314,166881,19453.5%
2025-07-29966,64010,5811,593,70160.7%
2025-07-28382,23662625,51061.1%
2025-07-25216,96749422,99051.3%
2025-07-24348,27623528,51765.9%
2025-07-23297,903583487,29761.1%
2025-07-22267,987172446,48960.0%
2025-07-21223,626380406,72955.0%
2025-07-18241,218108471,58951.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.